Reuters logo
BRIEF-Innate Pharma announces top-line results from EffiKIR trial
February 6, 2017 / 6:47 AM / 10 months ago

BRIEF-Innate Pharma announces top-line results from EffiKIR trial

Feb 6 (Reuters) - Innate Pharma SA :

* Innate Pharma announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab

* Study did not meet primary efficacy endpoint

* Confirms safety profile of lirilumab as a monotherapy

* Broad clinical program ongoing, investigating lirilumab in a variety of tumor indications and combinations

* No statistically significant difference between either lirilumab arms and placebo arm on leukemia-free survival (LFS) nor on other efficacy endpoints

* Adverse events encountered with lirilumab were consistent with previously reported safety profile of lirilumab Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below